I have tried to find Misslings source for 90% S1R WT prevalence a few times now and just can’t find it. I am assuming he is seeing that to be the case in our trials or he got the number from newly published reporting. In any case 84% + impressive.
I got my stat from a large independent genomic study.
Blarcamesine will be prescribed to ALL AD patients. There will likely be some therapeutic benefit to even the least responsive. And why not when it's safe to take?